- Home
- SLQT vs SGMT Comparison
SLQT vs SGMT Comparison
Compare SLQT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SLQT | SGMT |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.6M | 169.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLQT | SGMT |
|---|---|---|
| Price | $1.22 | $7.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $2.88 | ★ $26.13 |
| AVG Volume (30 Days) | 932.1K | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,526,594,000.00 | $2,000,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | $81.71 | ★ N/A |
| Revenue Growth | ★ 15.50 | N/A |
| 52 Week Low | $0.56 | $3.15 |
| 52 Week High | $2.80 | $11.41 |
Technical Indicators
Market Signals| Indicator | SLQT | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 74.40 | 61.81 |
| Support Level | $0.81 | $6.61 |
| Resistance Level | $2.17 | $7.86 |
| Average True Range (ATR) | 0.10 | 0.71 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 84.75 | 56.63 |
Price Performance
Historical ComparisonAbout SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.